Healthy meta benefit 7-aca price increase

Due to the production of some manufacturers, since September, domestic 7-aca prices continue to rise, there is analysis that the new capacity to invest in the Health Yuan (600380) will obviously benefit. It is understood that the current health yuan's main 7-aca capacity is concentrated in the subordinate Jiaozuo health Yuan Biological Products Co., Ltd., 7-aca is a kind of cephalosporin intermediates, starting from the fourth quarter of 2009, the price of the product gradually higher.　　Public information shows that in September 2010, 7-aca two times in one months, the price increases, respectively, 750 yuan/kg and 800 yuan/kg, October 12 further rise to 900 yuan/kg. Health Yuan released the first three quarterly Express, 2010 years ago net profit of 570 million yuan, compared with a year earlier year-on-year increase of 69.9% yuan, the main business profit is about 563 million, compared with the same period last year, up about 113%.　　Health Yuan Dong Chu Qingfung said in an interview with reporters: The first three quarter of this year, the main reason for the rapid increase in corporate performance is the company's main product price, of which 7-aca products in the first nine months of the average price is significantly higher than last year, and the company's second half of the year 7-aca product capacity has Jiaozuo Health Yuan has a monthly of about 100 tons of 7-aca capacity, since June this year, the Healthy Yuan 7-aca capacity further expansion, currently reached about 150 tons/month, and capacity at full load production status.　　2009, Jiaozuo Health Yuan 7-aca products to achieve a profit of only about 60 million yuan, and the first 9 months of this year, this product is expected to contribute to health yuan 240 million yuan, accounting for health yuan forecast net profit of more than 42%. Clearly, 7-aca is currently the main source of profit for the health yuan. However, the health yuan still has other key products. Health yuan subordinate Shenzhen Coastal Pharmaceutical Co., Ltd. mainly produces the south-class preparation and raw materials, including the United States faropenem preparations in the domestic market share of 44%. Chu Qingfung told reporters that the first three quarters of this year, the coastal pharmaceutical sales are very good, the rate control excellent.　　The company is actively preparing to enter the regulatory market, the certification work is the current focus. Wang Yu, an analyst with Societe Generale Securities, said in the domestic market, health yuan is reporting a number of south-class pharmaceutical products, the plan will be expanded to 7 varieties, through the rich variety to maintain or even expand in the domestic culture of the leading south-class agents; The international market, the company will be in the next year to declare the EU COS and FDA certification, including raw materials and preparations, to the United States Faropenem raw materials and a variety of pharmaceutical products into the European and American Standard market.